Please login to the form below

Not currently logged in
Email:
Password:

TT701

This page shows the latest TT701 news and features for those working in and with pharma, biotech and healthcare.

Transition takes on Lilly muscle-boosting drug

Transition takes on Lilly muscle-boosting drug

The big pharma company pockets just $1m upfront from the deal, although Transition could pay up to $100m in milestones if the small-molecule drug - called TT701 - eventually reaches the market. ... TT701 is a selective androgen receptor modulator (SARM)

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Transition Therapeutics with the out-licence of the phase II ready selective androgen receptor modulator TT701 to Transition. ... 105.5. Eli Lilly/ Transition Therapeutics. Licence agreement. For TT701 a selective androgen receptor modulator in P2 for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics